Jak and Todd

Promising Early Launch Metrics for AbbVie's Rinvoq (upadacitinib) to Help JAK Inhibitors Solidify Their Position as Second-Line Leaders in Rheumatoid Arthritis, According to Spherix Global Insights

Retrieved on: 
Monday, December 16, 2019

By comparison, Olumiant and Kevzara garnered a user-base of only 4% and 25%, respectively, at a similar time period post-launch.

Key Points: 
  • By comparison, Olumiant and Kevzara garnered a user-base of only 4% and 25%, respectively, at a similar time period post-launch.
  • Other brands anticipated to grow include Kevzara and Olumiant (though to a much lesser extent), while Xeljanz remains relatively flat.
  • With Rinvoq out of the pipeline picture, rheumatologists are more likely to prefer Gilead/Galapagos' filgotinib (JAK) and Merck's evobrutinib (BTK) over other developmental agents.
  • Spherix will continue to track the launch of Rinvoq over the next year.